The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy
Status:
Completed
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
Immunotherapy has made a major progress in Lung cancer.However, challenges such as primary
and acquired resistance, small fraction of benefit population and lack of predictive and
prognostic biomarkers even exist. The overall objective response rate is lower than 20% in
second line-treatment and the progression-free survival (PFS) is also similar to or poorer
than that of conventional second-line chemotherapy. Anlotinib is a novel, orally
administered, multitarget receptor tyrosine kinase inhibitor that inhibits VEGFR, PDGFR,
FGFR, c-Kit, and other kinases. It functions by inhibiting tumor angiogenesis and
proliferative signaling pathways. We would observe and analyze the effectiveness and safety
of anlotinib combined with Immune checkpoint inhibitors for advanced NSCLC after muti-line
therapy to explore the synergistic effect of anti-angiogenic agents and immunotherapy.